-
Pityriasiform drug eruption associated with venetoclax for acute myeloid leukaemia. Anti-Cancer Drugs (IF 2.3) Pub Date : 2024-03-22 Timothy J Liu, Erin K McMeniman
Venetoclax is a targeted antileukaemic therapy that has emerged as the primary treatment of acute myeloid leukaemia in patients of advanced age or who would otherwise be ineligible for standard chemotherapy. Despite the documented evidence of cutaneous side effects of venetoclax, few reports have clarified presenting cutaneous features beyond the descriptors 'rash' and 'pruritus'. In this report, we
-
Bergaptol inhibits glioma cell proliferation and induces apoptosis via STAT3/Bcl-2 pathway. Anti-Cancer Drugs (IF 2.3) Pub Date : 2024-03-22 Hao Huang, Junrong Zhang, Jianbing Wu, Chunfu Du, Bo Zheng, Zhangchao Guo, Ligang Chen, Deming Zhang, Luotong Liu
Glioblastoma (GBM) is the most common primary malignant brain tumour and lacks therapeutic options with significant effects. The aberrant activation of STAT3 is a critical factor in glioma progression via activating multiple signalling pathways that promote glioma. Among them, the antiapoptotic gene Bcl-2 could be upregulated by p-STAT3, which is an important reason for the continuous proliferation
-
Tislelizumab plus chemotherapy is an optimal option for second-line treatment for advanced gastroesophageal junction adenocarcinoma. Anti-Cancer Drugs (IF 2.3) Pub Date : 2024-03-22 Ping Yang, Tao Pan, Ming-Kun Wang, Meng-Sheng Xiao, Shuang Zhang, Sha Liu
The development of programmed cell death receptor-1 and its ligand (PD-L1) have offered new treatment options for several cancers, but the clinical benefit of tislelizumab in the gastroesophageal junction (GEJ) adenocarcinoma is still murky. Thus, we aim to investigate the efficacy and safety of tislelizumab combined with chemotherapy in patients with GEJ cancer. In this study, 90 GEJ patients were
-
Early dose reduction of osimertinib in advanced EGFR-mutated non-small cell lung cancer. Anti-Cancer Drugs (IF 2.3) Pub Date : 2024-03-22 Marion Ferreira, Matthew I Ebia, Karen L Reckamp
Osimertinib has become the standard of care for epidermal growth factor receptor (EGFR)-mutated non-small cell lung cancer (NSCLC). In order to prevent or treat toxicity, the osimertinib dose may be reduced. However, data regarding the impact of dose reduction during treatment are limited. We aimed to compare the efficacy of osimertinib early dose reduction during the first 3 months of treatment with
-
Network meta-analysis of first-line systemic regimens for older patients with advanced NSCLC. Anti-Cancer Drugs (IF 2.3) Pub Date : 2024-03-19 Andrea Luciani, Lorenzo Dottorini, Elena Battaiotto, Fausto Petrelli
Various immunotherapy treatments have received approval for the treatment of advanced non-small cell lung cancer (NSCLC), either as standalone or in conjunction with chemotherapy, contingent upon the extent of PD-L1 expression. These treatments are commonly utilized in clinical practice. However, a specific gap exists in direct comparisons of these regimens in elderly patients. The aim of this network
-
A comprehensive clinical evaluation of HER2-TKIs in patients with previously treated HER2-positive metastatic breast cancer. Anti-Cancer Drugs (IF 2.3) Pub Date : 2024-03-19 Wen-Jun Ji, Xuan Lu, Yu-Gang Wang, Lin-Wei Chen
Human epidermal growth factor receptor 2-tyrosine kinase inhibitors (HER2-TKIs) have been extensively utilized for treating HER2-positive metastatic breast cancer (MBC), with numerous clinical trial reports available. We aim to systematically perform a comprehensive clinical evaluation on HER2-TKIs, provide a reference for the clinical rational use of drugs, and serve for the decision-making of the
-
Brigatinib combined with cetuximab in the fifth-line treatment of non-small cell lung cancer with EGFR p.C797S mutation in critically ill patients: a report of two cases and literature review. Anti-Cancer Drugs (IF 2.3) Pub Date : 2024-03-15 Juanjuan Liu, Hongtao Lei, Ding Zhang, Ning Zhang
For critically ill patients with non-small cell lung cancer (NSCLC) in need of life-saving treatment, there is currently no reported evidence regarding the use of medication specifically targeting epidermal growth factor receptor (EGFR) p.C797S mutation, which is known to cause resistance to third-generation tyrosine kinase inhibitors (TKIs). Our report aims to investigate and explore treatment strategies
-
HOXA1 silencing inhibits cisplatin resistance of oral squamous cell carcinoma cells via IκB/NF-κB signaling pathway. Anti-Cancer Drugs (IF 2.3) Pub Date : 2024-03-12 Ruifeng Zhu, Yiting Mao, Xianzhi Xu, Yingying Li, Jiwei Zheng
The resistance of oral squamous cell carcinoma (OSCC) cells to cisplatin remains a tough nut to crack in OSCC therapy. Homeobox A1 (HOXA1) overexpression has been detected in head and neck squamous carcinoma (HNSC). Accordingly, this study aims to explore the potential role and mechanism of HOXA1 on cisplatin resistance in OSCC. The expression of HOXA1 in HNSC and its role in overall survival (OS)
-
m6A reader IGF2BP1 reduces the sensitivity of nasopharyngeal carcinoma cells to Taxol by upregulation of AKT2. Anti-Cancer Drugs (IF 2.3) Pub Date : 2024-03-12 Chong Zhao, Fang Zhang, Yang Tian, Bingjie Tang, Jing Luo, Jianhui Zhang
Taxol is widely used in the treatment of nasopharyngeal carcinoma (NPC); nevertheless, the acquired resistance of NPC to Taxol remains one of the major obstacles in clinical treatment. In this study, we aimed to investigate the role and mechanism of insulin-like growth factor 2 mRNA-binding protein 1 (IGF2BP1) in Taxol resistance of NPC. Taxol-resistant NPC cell lines were established by exposing to
-
HMOX1 regulates ferroptosis via mic14 and its impact on chemotherapy resistance in small-cell lung cancer. Anti-Cancer Drugs (IF 2.3) Pub Date : 2024-03-11 Yujie Sun, Jian Zhang
This study aimed to investigate the role and molecular mechanism of heme oxygenase-1 (HMOX1) in chemotherapy resistance in small-cell lung cancer (SCLC). Employed bioinformatics, qPCR, and Western Blot to assess HMOX1 levels in SCLC versus normal tissues and its prognostic relevance. CCK-8, flow cytometry, and thiobarbituric acid assays determined HMOX1's impact on SCLC chemosensitivity, ferroptosis
-
Anoikis-related lncRNA signature predicts prognosis and is associated with immune infiltration in hepatocellular carcinoma. Anti-Cancer Drugs (IF 2.3) Pub Date : 2024-03-11 Jiahong Zhu, Wenjing Zhao, Junkai Yang, Cheng Liu, Yilang Wang, Hui Zhao
Anoikis is a programmed cell death process triggered when cells are dislodged from the extracellular matrix. Numerous long noncoding RNAs (lncRNAs) have been identified as significant factors associated with anoikis resistance in various tumor types, including glioma, breast cancer, and bladder cancer. However, the relationship between lncRNAs and the prognosis of hepatocellular carcinoma (HCC) has
-
The efficacy and safety of adding anlotinib in gradual progression on third-generation EGFR-TKIs for EGFR-mutant advanced nonsmall cell lung cancer. Anti-Cancer Drugs (IF 2.3) Pub Date : 2024-02-23 Hai Xiang, Ding Danna, Chen Xuefei, Jinkai Zhao, Guangjun Jin
Acquired resistance is unavoidable with the approval of third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) for first-line therapy of advanced non small cell lung cancer (NSCLC). Some studies have found that combining antiangiogenesis medicines with EGFR-TKI may benefit clinical outcomes in EGFR-mutant NSCLC. However, it is unclear whether EGFR-TKI paired with
-
Urinary exosomal mRNA as a biomarker for the diagnosis of bladder cancer. Anti-Cancer Drugs (IF 2.3) Pub Date : 2024-02-23 Xinying Wang, Dianbin Song, Baoxing Zhu, Yang Jin, Caisen Cai, Zhiyong Wang
To study the diagnostic value of mRNA expression in urinary exocrine body in bladder cancer.
-
Neoadjuvant savolitinib targeted therapy for stage IIIB-N3 lung adenocarcinoma harboring mesenchymal-epithelial transition exon 14 skipping mutation: a case report and literature review. Anti-Cancer Drugs (IF 2.3) Pub Date : 2024-02-23 Lei Chen, Jin-Feng Chen, Jin-Tao He, Hao Rong, Xiang Zhuang, Jun Peng
Savolitinib is a selective inhibitor that specifically targets the phosphorylation of mesenchymal-epithelial transition (MET) kinase. It has demonstrated significant inhibitory effects on the proliferation of tumor cells with METex14 skipping mutation, making it a promising treatment option. While it is the first approved small-molecule inhibitor specifically targeting MET kinase in China, there is
-
Anlotinib plus Sintilimab achieved in an antitumor effect of complete remission in a patient with advanced hepatocellular carcinoma: a case report. Anti-Cancer Drugs (IF 2.3) Pub Date : 2024-02-23 Caiping Sun, Xiaoteng Ma, Liming Jiang, Xiaoling Zhu
Systemic therapies-based combination treatments have been developed rapidly in patients with advanced hepatocellular carcinoma (HCC). However, there are still a few patients not applicable to any recommended therapies, making it considerable to try new therapeutic options. Among them, anlotinib, a new oral tyrosine kinase inhibitor, is being widely used for many advanced malignancies. We present the
-
Plasma sPD-L1 and VEGF levels are associated with the prognosis of NSCLC patients treated with combination immunotherapy. Anti-Cancer Drugs (IF 2.3) Pub Date : 2024-02-23 Changhong Dong, Kaiyuan Hui, Jie Gu, Mei Wang, Chenxi Hu, Xiaodong Jiang
The clinical significance of plasma soluble programmed cell death ligand 1 (sPD-L1) and vascular endothelial growth factor (VEGF) for non-small cell lung cancer (NSCLC) treated with the combination of anti-angiogenic therapy and anti-PD-L1 antibody (Ab) remain unknown. This study aimed to explore the association between plasma sPD-L1 and VEGF levels and the prognosis of NSCLC patients treated with
-
Diagnostic and prognostic value of serum soluble B7-H3 in nonsmall cell lung cancer. Anti-Cancer Drugs (IF 2.3) Pub Date : 2024-02-23 Yinpeng Li, Leiqian Xu, Jing Li, Qian Wang, Jiao Ma
The aim of this study was to investigate the utility of serum soluble B7-H3 (sB7-H3) as a diagnostic marker for early-stage nonsmall cell lung cancer (NSCLC) and its potential for evaluating the prognosis of patients with advanced-stage NSCLC. In this study, an ELISA was employed to detect the expression levels of sB7-H3 in a cohort of patients diagnosed with NSCLC (n = 122) and a control group (n = 42)
-
NFATc2 promotes lactate and M2 macrophage polarization through USP17 in lung adenocarcinoma. Anti-Cancer Drugs (IF 2.3) Pub Date : 2024-02-23 Liang Wang, Yuanyuan Ma, Shanyuan Zhang, Yue Yang, Bo Huang
It is well known that immune cells including macrophages within the tumor microenvironment play an essential role in tumor progression. Here, we studied how NFATc2 regulated macrophage properties in lung adenocarcinoma. Higher expression of NFATc2 was observed in the lung adenocarcinoma tissues than in the normal lung tissues. Positive relationships were found between NFATc2 and genes associated with
-
Venetoclax combined with decitabine induced tumor lysis syndrome in a young patient with acute myeloid leukemia: a case report and literature review. Anti-Cancer Drugs (IF 2.3) Pub Date : 2024-02-23 Hongyong Zhang, Jingdi Liu, Qiuling Wu, Linghui Xia
Venetoclax, in combination with hypomethylation agents (HMAs), is a novel treatment for leukemia patients with low chemotherapy tolerance. However, it has been reported to be a risk of causing tumor lysis syndrome (TLS) in chronic lymphocytic leukemia (CLL) and elderly acute myeloid leukemia (AML) patients. Here we report a rare case of a young adult AML patient who induced TLS after receiving a combination
-
STK214947, a novel indole alkaloids, inhibits HeLa and SK-HEP-1 cells survival and EMT process by bloking the Notch3 and Akt signals. Anti-Cancer Drugs (IF 2.3) Pub Date : 2024-01-23 Zihan Xu, Yuxin Yuan, Jiaqi Liu, Caijing Li, Kejin Chen, Fang Wang, Ganpeng Li
Apoptosis and epithelial-to-mesenchymal transition (EMT) are closely associated with tumor survival and metastasis. These are the basic events in tumor occurrence and progression. STK214947 is an indole alkaloid with a skeleton that is similar to that of indirubin. Indole alkaloids have attracted considerable attention because of their antitumor activity. However, the relationship between STK214947
-
Experience with pembrolizumab in a renal transplant patient with advanced lung cancer: a case report and review. Anti-Cancer Drugs (IF 2.3) Pub Date : 2024-01-23 Laura Fernández Madrigal, Victoria García Samblásand, Laura Sánchez Escudero
The treatment of non-small cell lung cancer (NSCLC) has undergone a change due to the advancement of new therapies, like immune checkpoint inhibitors (ICIs), including pembrolizumab. A 64-year-old woman received a kidney transplant in 2012 due to chronic kidney disease secondary to glomerulosclerosis, diagnosed in 2020 with stage IV NSCLC due to metastasis in the contralateral lung, with PD-L1 expression
-
Nivolumab combined docetaxel versus nivolumab in patients with previously treated nonsmall cell lung cancer: a phase 2 study. Anti-Cancer Drugs (IF 2.3) Pub Date : 2024-01-22 Yang Wang, Qianyun Hao, Jun Nie, Ling Dai, Weiheng Hu, Jie Zhang, Xiaoling Chen, Xiangjuan Ma, Guangming Tian, Jindi Han, Sen Han, Di Wu, Jieran Long, Ziran Zhang, Jian Fang
The current standard second-line treatment is immune checkpoint inhibitors monotherapy for nonsmall cell lung cancer (NSCLC) patients. The objective of this phase 2 study was to evaluate the efficacy and safety of nivolumab plus docetaxel compared with nivolumab monotherapy for second-line therapy in immunotherapy-naive patients with advanced NSCLC. Progression-free survival (PFS) was the primary endpoint
-
APOC1 reduced anti-PD-1 immunotherapy of nonsmall cell lung cancer via the transformation of M2 into M1 macrophages by ferroptosis by NRF2/HO-1. Anti-Cancer Drugs (IF 2.3) Pub Date : 2024-01-22 Langhua Mei, Jian Long, Shue Wu, Meie Mei, Di Mei, Huaping Qiu
The treatment strategy for nonsmall cell lung cancer (NSCLC) has always been a hot topic of concern, and its treatment strategies are also emerging. This experiment wants to know the effects of apolipoprotein C1 (APOC1) in immunotherapy of NSCLC. APOC1 mRNA and protein expression were upregulated in lung cancer tissue of patients with NSCLC. programmed cell death protein 1 (PD-1) mRNA expression was
-
M6A methylation of FKFB3 reduced pyroptosis of gastric cancer by NLRP3. Anti-Cancer Drugs (IF 2.3) Pub Date : 2024-01-22 Wanyuan Chen, Xiaolin Ye, Yun Chen, Tongwei Zhao, Hongying Zhou
Gastric cancer is a kind of malignant tumor that seriously endangers human life and health. Its incidence rate and mortality rate are among the highest in the global malignant tumors. Therefore, this study explored the role of 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase 3 (PFKFB3) in the progression of gastric cancer and its underlying mechanism. Patients with gastric cancer were collected
-
Comparison of effects of tamoxifen and Toremifene on hepatic function and serum lipids in breast cancer patients during adjuvant endocrine therapy. Anti-Cancer Drugs (IF 2.3) Pub Date : 2024-01-22 Wenxia Wang, Xiao'an Liu
To investigate the effects of tamoxifen (TAM) and toremifene (TOR) on hepatic function and serum lipid levels in breast cancer patients receiving adjuvant endocrine therapy. The clinical data of 597 early breast cancer patients treated at the First Affiliated Hospital of Nanjing Medical University between January 2016 and December 2022 were collected. All the patients received standard adjuvant endocrine
-
Inhibition of mitochondrial function by approved drugs overcomes nasopharyngeal carcinoma chemoresistance. Anti-Cancer Drugs (IF 2.3) Pub Date : 2024-01-15 Yunlong Zhang, Difeng Guo, Yongbo Zhu, Lin Liu
The development of chemo-resistance in nasopharyngeal carcinoma (NPC) presents a significant therapeutic challenge, and its underlying mechanisms remain poorly understood. In our previous studies, we highlighted the association between isoprenylcysteine carboxylmethyltransferase (ICMT) and chemoresistance in NPC. In this current research, we revealed that both 5-FU and cisplatin-resistant NPC cells
-
Successful immunotherapy with PD-1 Iinhibitor for advanced pancreatic cancer: report of two cases and review of literature. Anti-Cancer Drugs (IF 2.3) Pub Date : 2024-01-08 Lijie Qiu, Chen Liu, Heping Li
Pancreatic cancer is a highly malignant tumor, and most patients are diagnosed at an advanced stage. Unfortunately, due to the immunosuppressive tumor microenvironment of pancreatic cancer, the benefits of immunotherapy for patients with advanced pancreatic cancer are still unclear. Here, we present two cases of advanced pancreatic cancer being controlled by immunotherapy, with pathological diagnoses
-
Silencing of KIF2C enhances the sensitivity of hepatocellular carcinoma cells to cisplatin through regulating the PI3K/AKT/MAPK signaling pathway. Anti-Cancer Drugs (IF 2.3) Pub Date : 2023-12-27 Shuxin Wei, Chunmiao Lu, Shutian Mo, Hailian Huang, Meifeng Chen, Shuai Li, Luping Kong, Hao Zhang, Pham Thi Thai Hoa, Chuangye Han, Xiaoling Luo
In the treatment of unresectable advanced hepatocellular carcinoma (HCC), cisplatin is administered transhepatic arterially for local treatment, but the clinical application of cisplatin drugs is frequently hindered by the emergence of drug resistance. Kinesin family member 2C(KIF2C) has been shown as oncogene in a variety of tumors. Nevertheless, its effect on cisplatin sensitivity has yet to be ascertained
-
Tumor neoantigens derived from RNA editing events show significant clinical relevance in melanoma patients treated with immunotherapy. Anti-Cancer Drugs (IF 2.3) Pub Date : 2023-12-27 Qicheng Lu, Wenhao Zhou, Ligang Fan, Tian Ding, Wei Wang, Xiaodong Zhang
This study aimed to investigate the clinical significance of RNA editing (RE) and RNA editing derived (RED-) neoantigens in melanoma patients treated with immunotherapy. Vardict and VEP were used to identify the somatic mutations. RE events were identified by Reditools2 and filtered by the custom pipeline. miRTar2GO was implemented to predict the RE whether located in miRNA targets within the 3' UTR
-
Ensartinib is effective in the treatment of advanced non-small-cell lung cancer with MET amplification after multi-line ALK-TKIs resistance: a case report. Anti-Cancer Drugs (IF 2.3) Pub Date : 2023-12-13 Yanping Yang, Xincheng He, Wenxuan Xiao, Jun Bai, Yi Liu
Although patients with ALK-positive non-small cell lung cancer (NSCLC) are initially effective on treatment with ALK tyrosine kinase inhibitors (TKIs), resistance will inevitably develop. Of these patients, 2/3 will develop ALK-independent resistance and little is known about the mechanisms of ALK-independent resistance. In pre-clinical studies, the activation of several bypass signaling pathways has
-
Clinical and radiological evaluation of a phyllodes tumor of the breast: a case report. Anti-Cancer Drugs (IF 2.3) Pub Date : 2023-12-13 Yan Huang, Guoyan Yao, Yun Wan
Phyllodes tumors (PTs) are rare breast tumors characterized by varying biological behavior and heterogeneous clinical findings. As a result, accurately diagnosing PTs preoperatively is challenging, often leading to misdiagnosis. A 49-year-old patient presented with a steadily growing right breast mass that had persisted over a 10-year period. Breast mammography and ultrasonography results indicated
-
Clusterin is upregulated by erastin, a ferroptosis inducer and exerts cytoprotective effects in pancreatic adenocarcinoma cells. Anti-Cancer Drugs (IF 2.3) Pub Date : 2023-12-13 Yichen Li, Xing Wang, Yong-Hua Chen, Qing-Quan Tan, Xu-Bao Liu, Chunlu Tan
Ferroptosis is a novel form of cell death, which is distinguished from apoptosis and necrosis, and characterized by accumulation of lipid-based reactive oxygen species (ROS) in an iron-dependent manner. Erastin, a small molecule, was widely reported to trigger ferroptosis in various kinds of cancer cells, including pancreatic cancer cells by inducing ROS accumulation. However, how erastin treatment
-
Case report outcome of cetuximab treatment in a metastatic colorectal cancer patient with novel KRAS P34R. Anti-Cancer Drugs (IF 2.3) Pub Date : 2023-11-29 Ruizhi Chen, Dongmei Yang, Yang Liu, Boquan Wang, Huiting Xu
Cetuximab [the epidermal growth factor receptor (EGFR)-targeting mAb] improves clinical outcomes when added to standard chemotherapy used in the treatment of metastatic colorectal cancer. Patients with hotspot mutations in Kirsten rat sarcoma viral oncogene (KRAS) mutation in exon 2 were not recommended to be treated with cetuximab. However, there is still a lack of clinical data for those unreported
-
Impact of antihistamine use on the survival outcomes of immune checkpoint inhibitors in advanced cancer patients. Anti-Cancer Drugs (IF 2.3) Pub Date : 2023-11-29 Eda Eylemer Mocan, Emre Yekedüz, Göktürk Karataş, Sati Coşkun Yazgan, Elif Berna Köksoy, Filiz Çay Şenler, Güngör Utkan, Ahmet Demirkazik, Hakan Akbulut, Yüksel Ürün
Histamine and H1 receptors play a crucial role in the tumor microenvironment. Preclinical data showed that concomitant use of antihistamines and immune checkpoint inhibitors (ICIs) might increase the effect of ICIs. This study aimed to evaluate the impact of antihistamines on the oncological outcomes of ICIs. This retrospective study was conducted in a tertiary cancer center. Advanced cancer patients
-
Design of potential anti-cancer agents as COX-2 inhibitors, using 3D-QSAR modeling, molecular docking, oral bioavailability proprieties, and molecular dynamics simulation. Anti-Cancer Drugs (IF 2.3) Pub Date : 2023-11-29 Mohammed Er-Rajy, Mohamed El Fadili, Abdelmoujoud Faris, Sara Zarougui, Menana Elhallaoui
Modeling the structural properties of novel morpholine-bearing 1, 5-diaryl-diazole derivatives as potent COX-2 inhibitor, two proposed models based on CoMFA and CoMSIA were evaluated by external and internal validation methods. Partial least squares analysis produced statistically significant models with Q 2 values of 0.668 and 0.652 for CoMFA and CoMSIA, respectively, and also a significant non-validated
-
HER2-positive advanced biliary tract cancer responds to second-line pyrotinib therapy: a case report. Anti-Cancer Drugs (IF 2.3) Pub Date : 2023-11-29 Linger Liu, Yao Chen, Xiaolian Zhu, Lisha Zhao, Baisong Chen
Biliary tract cancers are solid tumors with poor prognosis and over 70% of patients present in advanced stages. The efficacy of second-line treatment for patients who progressed on GC chemotherapy is limited. Median OS of these patients is less than 1 year with palliative treatment. Despite the success of anti-HER2 therapy in HER2-positive breast cancer, the targeted therapy of HER2 mutations in BTCs
-
Acute heart failure following pazopanib treatment: a literature review featuring two case reports. Anti-Cancer Drugs (IF 2.3) Pub Date : 2023-11-28 Neyran Kertmen, Gozde Kavgaci, Hasan Cagri Yildirim, Omer Dizdar
Tyrosine kinase inhibitors (TKIs) have transformed cancer treatment but are associated with cardiovascular toxicity, including heart failure. This review examines the cardiotoxicity of pazopanib, a VEGFR-TKI, through two case reports and explores potential mechanisms. The importance of vigilant clinical monitoring to prevent cardiac dysfunction in cancer patients receiving pazopanib is emphasized.
-
CALCRL induces resistance to daunorubicin in acute myeloid leukemia cells through upregulation of XRCC5/TYK2/JAK1 pathway. Anti-Cancer Drugs (IF 2.3) Pub Date : 2023-11-13 Shanhao Tang, Shuangyue Li, Xiaowei Shi, Lixia Sheng, Qitian Mu, Yi Wang, Huiling Zhu, Kaihong Xu, Miao Zhou, Zhijuan Xu, An Wu, Guifang Ouyang
Chemotherapy is the main treatment option for acute myeloid leukemia (AML), but acquired resistance of leukemic cells to chemotherapeutic agents often leads to difficulties in AML treatment and disease relapse. High calcitonin receptor-like (CALCRL) expression is closely associated with poorer prognosis in AML patients. Therefore, this study was performed by performing CALCRL overexpression constructs
-
Dual targeting of Mcl-1 and Bcl-2 to overcome chemoresistance in cervical and colon cancer. Anti-Cancer Drugs (IF 2.3) Pub Date : 2023-11-13 Ling Wang, Changlei Xi, Rong Liu, Tingting Ye, Ning Xiang, Jinfang Deng, Hui Li
After an initial positive response to chemotherapy, cancer patients often become resistant and experience relapse. Our previous research identified eukaryotic translation initiation factor 4E (eIF4E) as a crucial target to overcome chemoresistance. In this study, we delved further into the role and therapeutic potential of myeloid cell leukemia 1 (Mcl-1), an eIF4E-mediated target, in chemoresistance
-
Mechanism of gemcitabine combined with lobaplatin in interventional treatment of locally advanced cervical cancer. Anti-Cancer Drugs (IF 2.3) Pub Date : 2023-11-13 Yang Lin, Qiaoli Yang
In order to investigate the mechanism of gemcitabine combined with lobaplatin in the interventional treatment of locally advanced cervical cancer (LACC), 90 patients with LACC were divided into control group (oxaliplatin + gemcitabine) and experimental group (lobaplatin + gemcitabine) according to different perfusion drugs and embolization drugs, 45 cases in each group. They were treated with arterial
-
Delayed immune-related hepatitis after 24 months of pembrolizumab treatment: a case report and literature review. Anti-Cancer Drugs (IF 2.3) Pub Date : 2023-11-13 Fernando Salazar González, Cristel Andrea Quiñones Palacios, Alba Manzaneque Gordón, José María Mazarico Gallego, Alba Díaz, Gloria Molas Ferrer
Immune checkpoint inhibitors targeting the programmed cell death protein 1 (PD-1) pathway have revolutionized cancer immunotherapy by enhancing the immune system's ability to combat cancer cells. However, this innovative approach comes with a distinctive set of challenges, as these therapies can lead to immune-related adverse events (irAEs) due to their mechanism of action. The most common irAEs involve
-
Surufatinib combined camrelizumab as a valuable third-line rescue therapy for a patient with extensive-stage for small-cell lung cancer: a case report and literature review. Anti-Cancer Drugs (IF 2.3) Pub Date : 2023-11-13 Chi Pan, Tao Yu, Li Han, Daxuan Hao, Ming Yang, Lin Li, Laili Chu, Qingtao Ni
Lung cancer is one of the most common malignant tumors with the highest incidence. Gene mutations are rare in small-cell lung carcinoma (SCLC), resulting in targeted therapy being only a third-line recommendation. Surufatinib (Sulanda) is an oral angio-immune kinase inhibitor used to treat solid tumors. We report a case of SCLC treated with surufatinib combined with camrelizumab, with good therapeutic
-
Efficacy and safety of sintilimab combined with apatinib as third-line or above therapy for patients with advanced or metastatic gastric cancer. Anti-Cancer Drugs (IF 2.3) Pub Date : 2023-11-13 Loulu Gao, Lin Tang, Xiaoqian Li, Jieqiong Peng, Zixuan Hu, Bo Liu
This study aimed to evaluate the efficacy and safety of the combination of sintilimab and apatinib for the treatment of patients with advanced or metastatic gastric cancer (GC) and gastroesophageal junction (GEJ) cancer. This retrospective study analyzed data from 34 patients who had advanced or metastatic GC/GEJ cancer and received the combination therapy of sintilimab and apatinib as a third-line
-
Autophagy as a therapeutic mechanism to kill drug-resistant cancer cells. Anti-Cancer Drugs (IF 2.3) Pub Date : 2023-10-16 Laurence Booth, Jane L Roberts, Andrew Poklepovic, Paul Dent
Herein we discuss multiple pre-clinical projects developed by our group that have been translated into patients at Massey Cancer Center. Our work has used multi-kinase inhibitors, for example, sorafenib, regorafenib and neratinib, and combined with additional agents, for example, histone deacetylase inhibitors, the thymidylate synthase inhibitor pemetrexed, and PDE5 inhibitors. In broad-brush terms
-
Jackfruit waste: an invented anticancer therapy using Jacalin lectin from jackfruit seed. Anti-Cancer Drugs (IF 2.3) Pub Date : 2023-10-11 Puja Ghosh, Muhasina K M, Neelaxi Pandey, Duraiswamy Basavan
Every food source contains both edible and inedible waste components. Millions of tonnes of trash from the food business are made from fruits, and these wastes are containing higher-value medicinal components, such as alkaloids, flavonoids, phenolic contents, a huge amount of proteins and secondary metabolites. These bioactive phytoconstituents are being used for the treatment of many serious fatal
-
A late relapse thymoma and pure red cell aplasia case with an over 5 years of clinical response under everolimus. Anti-Cancer Drugs (IF 2.3) Pub Date : 2023-10-11 Elif B Köksoy, Hakan Akbulut
Although several agents showed some clinical activity in patients with recurrent thymoma, there is no standard treatment option. Here, we report a late relapse thymoma and pure red cell aplasia case, responsive to everolimus with over 5 years of clinical benefit following multiple lines of treatment. Everolimus controlled the rapidly progressive disease in our patient without significant toxicity.
-
Dinaciclib exerts a tumor-suppressing effect via β-catenin/YAP axis in pancreatic ductal adenocarcinoma. Anti-Cancer Drugs (IF 2.3) Pub Date : 2023-09-11 Yichen Li, Zhenjiang Zheng, Li Xiao, Yonghua Chen, Xubao Liu, Dan Long, Li Chai, Yi Li, Chunlu Tan
Dinaciclib, a cyclin-dependent kinase-5 (CDK5) inhibitor, has significant anti-tumor properties. However, the precise mechanism of dinaciclib requires further investigation. Herein, we investigated the anti-tumor functions and molecular basis of dinaciclib in pancreatic ductal adenocarcinoma (PDAC). PDAC and matched para-carcinoma specimens were collected from the patients who underwent radical resection
-
Hemodialysis requirement after the first dose of durvalumab following chemoradiation therapy: a case report. Anti-Cancer Drugs (IF 2.3) Pub Date : 2023-09-11 Chihiro Yamada, Fumihiro Kashizaki, Mai Kaneko, Daiyu Kitaji, Naomi Kawano, Takeshi Kaneko
Durvalumab is the first immune check point inhibitor that was approved for use following concurrent platinum-based chemoradiation, in patients with unresectable stage III non-small cell lung cancer. The new treatment regimen of durvalumab administered after chemoradiation resulted in higher response rates and required careful immune-related adverse effects management. We experienced a rare case of
-
Inhibition of MNK pathway sensitizes nasopharyngeal carcinoma to radiotherapy. Anti-Cancer Drugs (IF 2.3) Pub Date : 2023-09-11 Honglan Luo, Shiyong Huang
Improving the clinical management of nasopharyngeal carcinoma (NPC) is an unmet need owing to the high incidence of treatment failure caused by radioresistance. In our study, we observed increased phosphorylation of translation initiation factor 4E (eIF4E), regulated by MAP kinase-interacting kinase (MNK), in NPC cells following irradiation treatment. Using siRNA to deplete MNK, we found that radiation-induced
-
Research progress of CXCR3 inhibitors. Anti-Cancer Drugs (IF 2.3) Pub Date : 2023-09-11 Zhuo Yuan
The human CXCR3 receptor was initially identified and cloned in the mid-1990s. In the process of understanding CXCR3, it gradually found that it plays an important role in the process of a variety of diseases, including inflammation, immune diseases, cancer, cardiovascular diseases, central nervous system diseases, etc., which attracted the attention of many researchers. Subsequently, some small molecule
-
Molecular mechanisms of HCG18 in the sorafenib resistance of hepatocellular carcinoma. Anti-Cancer Drugs (IF 2.3) Pub Date : 2023-09-01 Heping Li, Jie Hu, Lijie Qiu, Yijiang Wu, Baiyin Zhong, Rong Ye, Binhui Xie
Sorafenib has been approved for advance hepatocellular carcinoma (HCC), however, drug resistance often occurred. Therefore, it is of great significance to clarify the underlying mechanisms of sorafenib resistance and to find out the effective strategies to overcome sorafenib resistance. The expression of HCG18 was detected by qPCR, MTT, colony formation, flow cytometry and TUNEL assay were used to
-
Cellular responses after (neratinib plus pemetrexed) exposure in NSCLC cells. Anti-Cancer Drugs (IF 2.3) Pub Date : 2023-08-31 Laurence Booth, Andrew Poklepovic, John F Hancock, Paul Dent
We previously demonstrated that neratinib interacted with pemetrexed to kill non-small cell lung cancer (NSCLC) cells. From developing other drug combinations, we observed that several days following exposure, cells activated survival mechanisms to counteract drug toxicity. The present studies attempted to define mechanisms that evolve to reduce the efficacy of neratinib and pemetrexed. Neratinib and
-
Venetoclax dose adjustment due to drug-drug interactions: a case report and literature review. Anti-Cancer Drugs (IF 2.3) Pub Date : 2023-08-25 Weibin Fan, Jun Guo, Yue Zhang, Runcong Zhang, Bin Lin
The primary aim of the study is to discuss the potential interactions between venetoclax and common drugs used in department of hematology and the corresponding effects on the efficacy and safety of venetoclax treatment. Here, we report an acute myeloid leukemia patient treated with venetoclax and posaconazole, and the dose of venetoclax was adjusted due to drug interactions. Clinical pharmacists actively
-
Trastuzumab deruxtecan (DS8201) for advanced non-small cell lung cancer with HER2 exon 20 insertion mutation: a case report. Anti-Cancer Drugs (IF 2.3) Pub Date : 2023-08-25 Xincheng He, Lei Hou, Jun Bai, Chao Sun, Dongjie Wang, Gaili An
An antibody-drug conjugate (ADC) of human epidermal growth factor receptor-2 (HER2) provides effective treatment for patients with HER2-positive non-small cell lung cancer (NSCLC). Exon 20 insertion mutations are the most common among HER2 mutations. This mutant subtype is highly drug-resistant, and patients receiving conventional treatment often have a poor prognosis. Trastuzumab deruxtecan (T-DXd)
-
M2 tumor-associated macrophage promoted DNA methylation in lung cancer metastasis via intensifying EZH2. Anti-Cancer Drugs (IF 2.3) Pub Date : 2023-08-25 Zheming Li, Jing Luo, Kaixiang Zhao, Jingjing Xu, Lilong Xia
This study aimed to explore the interaction between the tumor-associated macrophage (TAM) and enhancer of zeste homolog 2 (EZH2) in tumor microenvironment of lung cancer are obscure. M2 type of TAM was induced by interleukin-4 (IL-4) and interleukin-13 (IL-13) in RAW264.7 cells. Subsequently, the co-culture system of the M2 RAW264.7 treating LLC-1 cells were constructed to evaluate the cell proliferation
-
Auranofin inhibits the occurrence of colorectal cancer by promoting mTOR-dependent autophagy and inhibiting epithelial-mesenchymal transformation. Anti-Cancer Drugs (IF 2.3) Pub Date : 2023-08-25 Mei Zhang, Dong-Yuan Yang, Zhi-Yi He, Yu Wu, Xiu-Yun Tian, Qing-Yang Huang, Wang-Bo Ma, Min Deng, Qi-Zhi Wang, Shan-Jun Yan, Hai-Lun Zheng
Colorectal cancer (CRC) is one of the world's most common and deadly cancers. According to GLOBOCAN2020's global incidence rate and mortality estimates, CRC is the third main cause of cancer and the second leading cause of cancer-related deaths worldwide. The US Food and Drug Administration has approved auranofin for the treatment of rheumatoid arthritis. It is a gold-containing chemical that inhibits
-
AZD7762 induces CRBN dependent BAG3 degradation through ubiquitin-proteasome pathway. Anti-Cancer Drugs (IF 2.3) Pub Date : 2023-07-14 Yanli Liao, Chao Yuan, Mi Huang, WenXia Si, Duanzhuo Li, Weibin Wu, Shifa Zhang, Runkun Wu, Yi Quan, Xin Yu, Shengjie Liao
Protein degraders are currently under rapid development as a promising modality for drug discovery. They are compounds that orchestrate interactions between a target protein and an E3 ubiquitin ligase, prompting intracellular protein degradation through proteasomal pathway. More protein degraders identification will greatly promote the development of this field. BAG3 is widely recognized as an excellent
-
Non-small cell lung cancer patient with a rare UGP2-ALK fusion protein responded well to alectinib: a case report. Anti-Cancer Drugs (IF 2.3) Pub Date : 2023-07-14 Liulin Chen, Daifang Chu, Wangping Li, Haitao Zhang
Several rare anaplastic lymphoma kinase (ALK) fusions have been identified in patients with non-small cell lung cancer (NSCLC); however, their treatment is not currently uniform. alectinib has been commonly used to treat rare ALK fusions in patients with NSCLC. This is the first study to report the occurrence of a uridine diphosphate-glucose pyrophosphorylase 2 (UGP2)-ALK fusion in a patient with NSCLC
-
Successful treatment of severe lung cancer caused by third-generation EGFR-TKI resistance due to EGFR genotype conversion with afatinib plus anlotinib. Anti-Cancer Drugs (IF 2.3) Pub Date : 2023-07-07 Qing Li, Nengluan Xu, Ming Lin, Yusheng Chen, Hongru Li
Third-generation EGFR-TKIs can be used to treat advanced non-small cell lung cancer patients with T790M resistance mutation induced by first- or second-generation EGFR-TKIs. However, it will also result in drug resistance, and the resistance mechanisms of third-generation EGFR-TKIs are complex. Here we reported a patient diagnosed with advanced lung adenocarcinoma and EGFR positive in September 2016
-
Selpercatinib monotherapy in a Chinese patient with RET fusion/EGFR co-mutated nonsmall cell lung cancer from the Phase II LIBRETTO-321 study: a case report. Anti-Cancer Drugs (IF 2.3) Pub Date : 2023-06-02 Lin Wu, Ying Cheng, Dingzhi Huang, Yuping Sun, Chengzhi Zhou, Jianying Zhou, Ye Guo, Jingxin Shao, Wanli Zhang, Shun Lu
Rearranged during transfection (RET) fusions and epidermal growth factor receptor (EGFR) mutations are potent oncogenic drivers in patients with nonsmall cell lung cancer (NSCLC), but rarely co-exist. Concurrent RET/EGFR mutations have been reported in patients with NSCLC who develop resistance to EGFR tyrosine kinase inhibitors but are even less frequent in treatment-naïve patients. Consequently,